OIL
Director Trades
| Date | Director | Value |
|---|---|---|
| C. Farah | $23,474 | |
| C. Farah | $1,556 | |
| Camile Farah | $20,000 | |
| Ms Karen Borg | $2,119 | |
| Mr Ron Song | $21,250 | |
| Mr Robert Cooke | $6,102 |
Company News
Optiscan Imaging and Mayo Clinic to collaborate on robotic breast cancer surgery technology
Optiscan Imaging (ASX: OIL) and US medical group Mayo Clinic have joined forces to advance the development of a digital confocal laser endomicroscopic imaging system for use in robot-assisted breast cancer surgery. The two parties are conducting the work as part of the 24-month “know-how” agreement they signed in May 2024, bringing together experts from […]
Optiscan Imaging completes beta phase testing of cloud-based telepathology platform
Commercial-stage medical technology company Optiscan Imaging (ASX: OIL) has completed beta phase testing of its cloud-based telepathology platform developed in partnership with Prolucid Technologies. The platform is believed to represent a significant advancement in digital pathology, enabling real-time collaboration on patient imaging sessions and allowing remote users to make immediate and informed decisions. The phase […]
Optiscan reveals InVue real-time imaging device for precision surgery
Optiscan Imaging (ASX: OIL) has revealed the InVue microscopic medical imaging device, designed to benefit the surgical market by providing real-time digital pathology access to surgeons. The Australian-made device was developed in partnership with local product development company Design + Industry for use in a wide range of clinical settings including cancer diagnosis and treatment. […]
Diagnostic imaging: which stock will become the next Pro Medicus?
For all the leaps and bounds in medical science, the know-how behind detecting diseases hasn’t changed much in decades – or even centuries. Take X-rays, which are widely used despite the wee problem of irradiating the patients. And that’s because they are cheap and convenient. The underlying tech hasn’t really moved on since 1895, when […]
Optiscan secures major milestone after approval for prestigious cancer trial
Medical equipment maker Optiscan Imaging (ASX: OIL) has achieved a significant milestone as part of its overarching development strategy after its cutting-edge “virtual biopsy technology” was selected for use in an oral cancer clinical trial, set to commence in the “near term”. Earlier today, Optiscan confirmed that its novel system and confocal laser endomicroscope technology […]
Company Videos
No videos found.